title: Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation.
abstract: BACKGROUND
  Patients harboring sensitive epidermal growth factor receptor (EGFR) mutations show a dramatic response to treatment with EGFR tyrosine kinase inhibitors (TKIs). However, there have been no clinical reports in lung cancer patients that compare the time-to-response between radiotherapy and EGFR-TKIs.
  
  
  METHODS
  We reviewed 17 and 32 consecutive patients with inoperable stage III/IV NSCLC who harbored sensitive EGFR mutations and who were treated with thoracic radiotherapy with or without chemotherapy and EGFR-TKIs, respectively.
  
  
  RESULTS
  There were statistically significant differences in time-to-partial response (PR) with regard to the treatment modalities (radiotherapy vs. EGFR-TKIs, median 57 days vs. 22 days, log-rank test, p=0.008).
  
  
  CONCLUSIONS
  EGFR-TKIs elicit tumor shrinkage earlier than does radiotherapy in patients with a sensitive EGFR mutation, suggesting that EGFR-TKIs may be useful for early symptom improvement in these patients.
authors.affiliation: Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-chou, Suntou-gun, Shizuoka 411-8777, Japan. m06701014@gunma-u.ac.jp
authors.forename: Hisao
authors.initials: H
authors.lastname: Imai
authors.forename: Takehito
authors.initials: T
authors.lastname: Shukuya
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Takahashi
authors.forename: Sakae
authors.initials: S
authors.lastname: Fujiwara
authors.forename: Keita
authors.initials: K
authors.lastname: Mori
authors.forename: Akira
authors.initials: A
authors.lastname: Ono
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Akamatsu
authors.forename: Tetsuhiko
authors.initials: T
authors.lastname: Taira
authors.forename: Hirotsugu
authors.initials: H
authors.lastname: Kenmotsu
authors.forename: Tateaki
authors.initials: T
authors.lastname: Naito
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Kaira
authors.forename: Haruyasu
authors.initials: H
authors.lastname: Murakami
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Harada
authors.forename: Masahiro
authors.initials: M
authors.lastname: Endo
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakajima
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Yamamoto
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000532:radiotherapy*; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D009367:Neoplasm Staging; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D013902:Radiography, Thoracic; D011878:Radiotherapy; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors
keywords: Epidermal growth factor receptor tyrosine kinase inhibitor; erlotinib; gefitinib; non-small cell lung cancer; radiotherapy